Trial Profile
An open trial to assess the tolerability of AVANZ Olive immunotherapy [Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Olivo]
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Olea pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis; Asthma
- Focus Adverse reactions
- Sponsors ALK-Abello
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 28 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01674595).
- 28 Aug 2012 Planned End Date changed from 10 Oct 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.